Anti-Factor B Antibodies and Acute Postinfectious GN in Children.


Journal

Journal of the American Society of Nephrology : JASN
ISSN: 1533-3450
Titre abrégé: J Am Soc Nephrol
Pays: United States
ID NLM: 9013836

Informations de publication

Date de publication:
04 2020
Historique:
received: 28 08 2019
accepted: 26 12 2019
pubmed: 9 2 2020
medline: 11 11 2020
entrez: 9 2 2020
Statut: ppublish

Résumé

The pathophysiology of the leading cause of pediatric acute nephritis, acute postinfectious GN, including mechanisms of the pathognomonic transient complement activation, remains uncertain. It shares clinicopathologic features with C3 glomerulopathy, a complement-mediated glomerulopathy that, unlike acute postinfectious GN, has a poor prognosis. This retrospective study investigated mechanisms of complement activation in 34 children with acute postinfectious GN and low C3 level at onset. We screened a panel of anticomplement protein autoantibodies, carried out related functional characterization, and compared results with those of 60 children from the National French Registry who had C3 glomerulopathy and persistent hypocomplementemia. All children with acute postinfectious GN had activation of the alternative pathway of the complement system. At onset, autoantibodies targeting factor B (a component of the alternative pathway C3 convertase) were found in a significantly higher proportion of children with the disorder versus children with hypocomplementemic C3 glomerulopathy (31 of 34 [91%] versus 4 of 28 [14%], respectively). In acute postinfectious GN, anti-factor B autoantibodies were transient and correlated with plasma C3 and soluble C5b-9 levels. We demonstrated that anti-factor B antibodies enhance alternative pathway convertase activity These findings elucidate the pathophysiologic mechanisms underlying acute postinfectious GN by identifying anti-factor B autoantibodies as contributing factors in alternative complement pathway activation. At onset of a nephritic syndrome with low C3 level, screening for anti-factor B antibodies might help guide indications for kidney biopsy to avoid misdiagnosed chronic glomerulopathy, such as C3 glomerulopathy, and to help determine therapy.

Sections du résumé

BACKGROUND
The pathophysiology of the leading cause of pediatric acute nephritis, acute postinfectious GN, including mechanisms of the pathognomonic transient complement activation, remains uncertain. It shares clinicopathologic features with C3 glomerulopathy, a complement-mediated glomerulopathy that, unlike acute postinfectious GN, has a poor prognosis.
METHODS
This retrospective study investigated mechanisms of complement activation in 34 children with acute postinfectious GN and low C3 level at onset. We screened a panel of anticomplement protein autoantibodies, carried out related functional characterization, and compared results with those of 60 children from the National French Registry who had C3 glomerulopathy and persistent hypocomplementemia.
RESULTS
All children with acute postinfectious GN had activation of the alternative pathway of the complement system. At onset, autoantibodies targeting factor B (a component of the alternative pathway C3 convertase) were found in a significantly higher proportion of children with the disorder versus children with hypocomplementemic C3 glomerulopathy (31 of 34 [91%] versus 4 of 28 [14%], respectively). In acute postinfectious GN, anti-factor B autoantibodies were transient and correlated with plasma C3 and soluble C5b-9 levels. We demonstrated that anti-factor B antibodies enhance alternative pathway convertase activity
CONCLUSIONS
These findings elucidate the pathophysiologic mechanisms underlying acute postinfectious GN by identifying anti-factor B autoantibodies as contributing factors in alternative complement pathway activation. At onset of a nephritic syndrome with low C3 level, screening for anti-factor B antibodies might help guide indications for kidney biopsy to avoid misdiagnosed chronic glomerulopathy, such as C3 glomerulopathy, and to help determine therapy.

Identifiants

pubmed: 32034108
pii: ASN.2019080851
doi: 10.1681/ASN.2019080851
pmc: PMC7191928
doi:

Substances chimiques

Autoantibodies 0
Complement C3 0
Complement C3 Nephritic Factor 0
Complement Factor B EC 3.4.21.47

Types de publication

Journal Article Meta-Analysis Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

829-840

Commentaires et corrections

Type : CommentIn
Type : CommentIn

Informations de copyright

Copyright © 2020 by the American Society of Nephrology.

Références

Adv Anat Pathol. 2012 Sep;19(5):338-47
pubmed: 22885383
Clin J Am Soc Nephrol. 2013 Apr;8(4):554-62
pubmed: 23307876
Kidney Int. 2015 Nov;88(5):1153-60
pubmed: 26221755
Isr Med Assoc J. 2016 Jun;18(6):336-40
pubmed: 27468526
Pediatr Nephrol. 2010 May;25(5):947-51
pubmed: 20108004
J Am Soc Nephrol. 2004 Mar;15(3):787-95
pubmed: 14978182
Proc Natl Acad Sci U S A. 2007 Jan 2;104(1):240-5
pubmed: 17182750
Clin J Am Soc Nephrol. 2018 Mar 7;13(3):406-413
pubmed: 29326307
Am J Kidney Dis. 2016 Dec;68(6):944-948
pubmed: 27683044
J Immunol. 2015 Jun 1;194(11):5129-38
pubmed: 25917093
Kidney Int. 2013 Dec;84(6):1079-89
pubmed: 24172683
Nature. 2015 Oct 1;526(7571):68-74
pubmed: 26432245
Hum Mutat. 2010 Jun;31(6):E1445-60
pubmed: 20513133
Nat Rev Nephrol. 2019 Mar;15(3):129-143
pubmed: 30692664
Kidney Int. 2017 Nov;92(5):1232-1241
pubmed: 28712854
Pediatr Int. 2018 Jul;60(7):645-650
pubmed: 29729114
Clin J Am Soc Nephrol. 2019 Mar 7;14(3):364-377
pubmed: 30674459
Nat Immunol. 2009 Jul;10(7):721-7
pubmed: 19503103
J Am Soc Nephrol. 2017 May;28(5):1603-1613
pubmed: 28096309
Kidney Int. 2014 Feb;85(2):450-6
pubmed: 24067430
Kidney Int. 2017 Mar;91(3):539-551
pubmed: 27989322
J Am Soc Nephrol. 2014 Sep;25(9):2053-65
pubmed: 24652797
Kidney Int. 2013 Feb;83(2):293-9
pubmed: 23235567
J Med Genet. 2003 Sep;40(9):676-81
pubmed: 12960213
J Am Soc Nephrol. 2004 Jul;15(7):1785-93
pubmed: 15213266
Kidney Int Suppl (2011). 2012 Jun;2(2):200-208
pubmed: 25018934
Pediatr Nephrol. 2016 Nov;31(11):2079-86
pubmed: 27008643
Clin Infect Dis. 1992 Jan;14(1):251-62
pubmed: 1571441
Science. 2010 Dec 24;330(6012):1816-20
pubmed: 21205667
Blood. 2013 Aug 22;122(8):1487-93
pubmed: 23847193
Kidney Int. 2012 Aug;82(4):454-64
pubmed: 22456601
N Engl J Med. 2011 Dec 15;365(24):2340-2
pubmed: 22168663
Lancet Infect Dis. 2005 Nov;5(11):685-94
pubmed: 16253886
J Immunol. 1979 Aug;123(2):755-8
pubmed: 379217
Nat Struct Mol Biol. 2007 Mar;14(3):224-8
pubmed: 17310251

Auteurs

Sophie Chauvet (S)

Inflammation, Complement and Cancer Team, Cordeliers Research Center, Institut National de la Santé et de la Recherche Médicale (INSERM) Unité Mixte de Recherche (UMR) S1138, Paris, France.
Departments of Nephrology and.
Paris University, Paris, France.

Romain Berthaud (R)

Paris University, Paris, France.
Department of Pediatric Nephrology, AP-HP, Necker Hospital - Sick Children, Paris, France.

Magali Devriese (M)

Immunology, Assistance Publique-Hôpitaux de Paris (AP-HP), Georges Pompidou European Hospital, Paris, France.

Morgane Mignotet (M)

Immunology, Assistance Publique-Hôpitaux de Paris (AP-HP), Georges Pompidou European Hospital, Paris, France.

Paula Vieira Martins (P)

Immunology, Assistance Publique-Hôpitaux de Paris (AP-HP), Georges Pompidou European Hospital, Paris, France.

Tania Robe-Rybkine (T)

Inflammation, Complement and Cancer Team, Cordeliers Research Center, Institut National de la Santé et de la Recherche Médicale (INSERM) Unité Mixte de Recherche (UMR) S1138, Paris, France.

Maria A Miteva (MA)

Paris University, Paris, France.
INSERM U1268 Medicinal Chemistry and Translational Research, Cibles Thérapeutiques et Conception du Médicament UMR8038 Centre National de la Recherche Scientifique (CNRS), Paris, France.

Aram Gyulkhandanyan (A)

University of Paris Diderot, Sorbonne Paris Cité, Molécules Thérapeutiques In Silico, INSERM UMR S973, Paris, France.

Amélie Ryckewaert (A)

Department of Nephrology, Rennes Hospital, Rennes, France.

Ferielle Louillet (F)

Department of Pediatric Nephrology, Rouen Hospital, Rouen, France.

Elodie Merieau (E)

Department of Pediatric Nephrology, Tours Hospital, Tours, France.

Guillaume Mestrallet (G)

Department of Pediatry, Villefranche sur Soane Hospital, Villefranche sur Soane, France.

Caroline Rousset-Rouvière (C)

Department of Pediatric Nephrology, Timone Hospital, Marseille, France.

Eric Thervet (E)

Departments of Nephrology and.
Paris University, Paris, France.

Julien Hogan (J)

Department of Pediatric Nephrology, AP-HP, Robert Debré Hospital, Paris, France.

Tim Ulinski (T)

Department of Pediatric Nephrology, AP-HP, Trousseau Hospital, Paris, France.

Bruno O Villoutreix (BO)

Paris University, Paris, France.
Laboratory of cristallography and biological Nuclear magnetic resonance, UMR 8015 CNRS, Paris, France; and.

Lubka Roumenina (L)

Inflammation, Complement and Cancer Team, Cordeliers Research Center, Institut National de la Santé et de la Recherche Médicale (INSERM) Unité Mixte de Recherche (UMR) S1138, Paris, France.

Olivia Boyer (O)

Paris University, Paris, France.
Department of Pediatric Nephrology, AP-HP, Necker Hospital - Sick Children, Paris, France.
Reference Center for Hereditary Kidney and Childhood Diseases (MARHEA), Imagine Institute, Paris, France.

Véronique Frémeaux-Bacchi (V)

Inflammation, Complement and Cancer Team, Cordeliers Research Center, Institut National de la Santé et de la Recherche Médicale (INSERM) Unité Mixte de Recherche (UMR) S1138, Paris, France; veronique.fremeaux-bacchi@aphp.fr.
Immunology, Assistance Publique-Hôpitaux de Paris (AP-HP), Georges Pompidou European Hospital, Paris, France.
Paris University, Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH